DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Involvement of Bcl-2 Family Proteins in Tetraploidization-Related Senescence
The B-cell lymphoma 2 (Bcl-2) family of proteins is the main regulator of apoptosis. However, multiple emerging evidence has revealed that Bcl-2 family proteins are also involved in cellular senescence. On the one hand, the different expression of these proteins determines the entry into senescence. On the other hand, entry into senescence modulates the expression of these proteins, generally conferring resistance to apoptosis. With some exceptions, senescent cells are characterized by the upregulation of antiapoptotic proteins and downregulation of proapoptotic proteins. Under physiological conditions, freshly formed tetraploid cells die by apoptosis due to the tetraploidy checkpoint. However, suppression of Bcl-2 associated x protein (Bax), as well as overexpression of Bcl-2, favors the appearance and survival of tetraploid cells. Furthermore, it is noteworthy that our laboratory has shown that the joint absence of Bax and Bcl-2 antagonist/killer (Bak) favors the entry into senescence of tetraploid cells. Certain microtubule inhibitory chemotherapies, such as taxanes and vinca alkaloids, induce the generation of tetraploid cells. Moreover, the combined use of inhibitors of antiapoptotic proteins of the Bcl-2 family with microtubule inhibitors increases their efficacy. In this review, we aim to shed light on the involvement of the Bcl-2 family of proteins in the senescence program activated after tetraploidization and the possibility of using this knowledge to create a new therapeutic strategy targeting cancer cells., L.S. was supported by the Spanish Agencia Estatal de Investigación, AEI (grant number PID2021-126426OB-I00), the Strategic Program from the Institute of Biomedicine and Molecular Genetics (IBGM) of Valladolid (CCVC8485) and the Internationalization Project of the Unit of Excellence IBGM of Valladolid from the Junta de Castilla y León (CL-EI-2021 IBGM), as well as the “Beatriz Galindo senior” Program from the Spanish Ministry of Universities. G.K. was supported by the Ligue contre le Cancer (équipe labellisée), Agence National de la Recherche (ANR)—Projets blancs, AMMICa US23/CNRS UMS3655, Association pour la recherche sur le cancer (ARC), Cancéropôle Ile-de-France, European Research Council Advanced Investigator Grand “ICD-Cancer”, Fondation pour la Recherche Médicale (FRM), a donation by Elior, Equipex Onco-Pheno-Screen, European Joint Programme on Rare Diseases (EJPRD), European Research Council (ICD-Cancer), European Union Horizon 2020 Projects Oncobiome and Crimson, Fondation Carrefour, Institut National du Cancer (INCa), Institut Universitaire de France, LabEx Immuno-Oncology (ANR-18-IDEX-0001), a Cancer Research ASPIRE Award from the Mark Foundation, the RHU Immunolife, Seerave Foundation, SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE) and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001. D.B. and R.P.-R. were supported by the University of Valladolid. L.G.-G. was supported by the “Margarita Salas” Program from the Spanish Ministry of Universities., Peer reviewed
Proyecto:
AEI PID2021-126426OB-I00